Cardiovascular problems: Melanotan may affect the cardiovascular system, potentially leading to issues such as changes in blood pressure, increased heart rate, and, in some cases, arrhythmia (irregular heartbeat)
The rarity of the lesion, which may present at different localizations create difficulty in placing a correct initial diagnosis
Contact your GP, trial team, or call NHS 111 promptly if you experience: Diarrhoea that is severe, bloody, or persists for more than 4872 hours without improvement Signs of dehydration, including dizziness, reduced urine output, dry mouth, or confusion Significant abdominal pain, particularly if severe or radiating to the back this may rarely indicate pancreatitis, a recognised risk associated with GLP-1-based therapies Pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice) these may suggest gallbladder disease, another recognised complication of this drug class [23] [24] Severe constipation, abdominal distension, or inability to pass wind or stools these may rarely indicate intestinal obstruction or ileus, for which the MHRA and EMA have issued safety communications in relation to GLP-1 receptor agonists [11] [12] Unexplained weight loss beyond what is expected from the treatment Vomiting that prevents adequate fluid or food intake Call 999 or go to your nearest A&E immediately if symptoms are severe, rapidly worsening, or you are unable to keep any fluids down
It cannot be emphasized enough how much genital melanosis clinically resembles melanoma and how little use simple guides for identifying melanomas (such as the widely publicized ABCDE approach) are in separating melanosis from melanoma
Inflammation and Immune Studies Research has noted possible connections between MT-1 and the suppression of neuroinflammation
Its cyclic structure makes it more resistant to enzymatic degradation, allowing it to remain active in the system for a longer period
